UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 13, 2008
ANGIOTECH PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
| | |
BRITISH COLUMBIA | 000-30334 | 98-0226269 |
(State or other jurisdiction of incorporation) | (Commission file number) | (IRS employer identification no.) |
| |
1618 Station Street, Vancouver, BC, Canada | V6A 1B6 |
(Address of principal executive offices) | (Zip code) |
Registrant’s telephone number, including area code: (604) 221-7676
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the fling obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| |
ITEM 5.02 | DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
On May 13, 2008, Angiotech Pharmaceuticals, Inc. issued a press release announcing the appointment of Dr. Henry A. McKinnell to its Board of Directors. Dr. McKinnell’s appointment was effective on May 12, 2008. The full text of Angiotech's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 5.02 of this Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| ANGIOTECH PHARMACEUTICALS, INC. | |
| | |
| | | |
Date: May 13, 2008 | By: | /s/ K. Thomas Bailey | |
| | Name: K. Thomas Bailey | |
| | Title: Chief Financial Officer | |
| | | |
EXHIBIT INDEX
